Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Working Capital Changes: 2017-2025

Historic Other Working Capital Changes for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $67,000.

  • UroGen Pharma's Other Working Capital Changes fell 96.37% to $67,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 2.72%. This contributed to the annual value of -$1.4 million for FY2024, which is 75.12% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Other Working Capital Changes is $67,000, which was up 107.22% from -$928,000 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Other Working Capital Changes peaked at $4.1 million during Q1 2025, and registered a low of -$5.8 million during Q4 2023.
  • Moreover, its 3-year median value for Other Working Capital Changes was $577,000 (2023), whereas its average is $92,818.
  • The largest annual percentage gain for UroGen Pharma's Other Working Capital Changes in the last 5 years was 2,170.55% (2023), contrasted with its biggest fall of 1,202.87% (2023).
  • UroGen Pharma's Other Working Capital Changes (Quarterly) stood at $1.4 million in 2021, then crashed by 61.67% to $522,000 in 2022, then plummeted by 1,202.87% to -$5.8 million in 2023, then rose by 9.54% to -$5.2 million in 2024, then slumped by 96.37% to $67,000 in 2025.
  • Its Other Working Capital Changes stands at $67,000 for Q3 2025, versus -$928,000 for Q2 2025 and $4.1 million for Q1 2025.